| 2026-08-14 | Earnings deck | Outlook Therapeutics Earnings Presentation |
| 2026-08-14 | Press release | Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting |
| 2026-08-12 | Press release | Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants |
| 2026-08-12 | Press release | Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants |
| 2026-08-06 | Press release | Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference C |
| 2026-07-31 | Presentation | Corporate Presentation: August 2026 |
| 2026-07-24 | Press release | Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the |
| 2026-06-16 | Press release | Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevac |
| 2026-06-01 | Press release | Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevaciz |
| 2026-05-28 | Press release | Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rule |
| 2026-05-26 | Press release | Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg) |
| 2026-05-15 | Press release | Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update |
| 2026-04-23 | Press release | Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering |
| 2026-04-22 | Press release | Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules |
| 2026-04-21 | Press release | Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vik |
| 2026-04-07 | Press release | Press release |
| 2026-04-07 | Press release | Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by F |
| 2026-03-05 | Press release | Press release |
| 2026-03-05 | Press release | Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg) |
| 2026-02-19 | Press release | Press release |
| 2026-02-19 | Press release | Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for |
| 2026-02-17 | Press release | Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update |
| 2026-02-11 | Press release | Press release |
| 2026-02-11 | Press release | Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter |
| 2025-12-19 | Press release | Outlook Therapeutics Reports Financial Results for Fiscal Year 2025 |
| 2025-08-14 | Press release | Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update |
| 2025-05-15 | Press release | Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update |
| 2025-03-04 | Regulatory report | 0000000000-25-002399.pdf |
| 2025-02-14 | Press release | Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update |
| 2024-12-27 | Press release | Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update |
| 2024-08-14 | Press release | Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update |
| 2024-05-15 | Press release | Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update |
| 2024-02-14 | Press release | Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update |
| 2023-12-22 | Press release | Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and Regulatory Pat |
| 2023-08-14 | Press release | Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2023 and Reiterates Key Anticipated Near-T |